## **ASX ANNOUNCEMENT**

9 June 2021

## **Probiotec Limited (ASX: PBP) Board Renewal**

Probiotec Ltd (ASX:PBP) today announces that its Chairman, Mr Sandy Beard, has advised he will be standing down from the role of Chairman effective 30 June 2021. Mr Beard has offered to facilitate a smooth board transition and will remain as a Non-Executive Director until after the Company appoints a replacement.

Mr Beard, who joined the board in November 2017, has indicated that due to significant new business commitments he can no longer dedicate the required attention to the role.

Chief Executive Officer of PBP, Mr Wes Stringer said: "on behalf of our board, staff and shareholders, I would like to thank Sandy for his leadership and significant contribution to the company over the past three and a half years. During this time, PBP has undergone a period of significant growth both organically and via strategic acquisitions, including the recent transformative acquisition of the Multipack-LJM group. Sandy has also provided practical support to the executive as we have all managed the unprecedented challenges that have arisen due to the Covid-19 pandemic.

"Whilst we are sad to see Sandy leave, the board wishes him the best and sincerely thanks him for his service and dedication".

The board has resolved that Jonathan Wenig will assume the role as Chairman. Since joining the board, Jonathan's leadership, commercial acumen and work ethic have made him a clear choice for the role and an outstanding addition for Probiotec.

Mr Wenig said "I am thrilled to accept the role of chairman and help to guide the company on the next stage of its growth as we look to continue the strong momentum of the recent past".

The Company has commenced a search process for an appropriate Non-Executive Director with a view to making an appointment in the near future.













ABN 91 075 170 151

## **About Probiotec**

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines, FMCG and consumer health products. The company owns five manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international companies.

Further details about Probiotec are available at www.probiotec.com.au

## For further information contact:

Wes Stringer **Managing Director** Ph: (03) 9278 7555

Authorised for release by the Probiotec Board of Directors.







